Issue Date: January 20, 2014
RNA Drug Firms Attract Deals
Small companies developing RNA-based therapeutics are finding eager partners. In less than a week, Alnylam Pharmaceuticals, Santaris Pharma, and Moderna Therapeutics announced drug development agreements totaling more than $1 billion.
The deals follow a year of significant accomplishments, says Cowen & Co. stock analyst Nicholas Bishop. He points to advances in RNA drug delivery and FDA approval of the first RNA-based drug, the cholesterol fighter Kynamro developed by Isis Pharmaceuticals and
You Do Not Have Access to C&EN Protected Content.